Getting On – And Staying In – the EMA’s PRIME Scheme
Executive Summary
Companies won’t necessarily lose their place on the European Medicines Agency’s priority medicines scheme if a competing product gets to market first. And they shouldn’t be put off by the fact that competing products are already on the scheme.